The European Commission issued hundreds of millions of dollars on pharmaceutical makers including France’s Servier for pay-for-delay deals that were found to have distorted the market, according to reports.
Servier and five generic drug makers were fined a combined $580 million for colluding to prevent generic and cheaper forms of medication from hitting store shelves in deals known as pay-for-delay. The medicine under scrutiny is Perindopril, which is used to treat blood pressure issues.
The collusion lead to Servier “systematically buying out any competitive threats,” said European Commissioner Joaquin Almunia, who also called the actions “clearly anticompetitive and abusive.”
Servier itself must pay $450 million, reports said.
Full content: ABC News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canadian Breadmakers Settle Price-Fixing Lawsuit
Jul 25, 2024 by
CPI
EssilorLuxottica Open to Meta as Shareholder, Says CEO Francesco Milleri
Jul 25, 2024 by
CPI
California Supreme Court Upholds Proposition 22, Securing Independent Contractor Status for Uber and Lyft Drivers
Jul 25, 2024 by
CPI
Paramount Global Investor Sues to Block Skydance Media Merger
Jul 25, 2024 by
CPI
Software Vendors Win Class Action Status in Antitrust Case Against CDK Global
Jul 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI